Ülke: Kanada
Dil: İngilizce
Kaynak: Health Canada
CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE); DEXAMETHASONE
NOVARTIS PHARMACEUTICALS CANADA INC
S02CA06
DEXAMETHASONE AND ANTIINFECTIVES
0.3%; 0.1%
SUSPENSION
CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 0.3%; DEXAMETHASONE 0.1%
OTIC
7.5ML
Prescription
ANTIBACTERIALS
Active ingredient group (AIG) number: 0250083001; AHFS:
APPROVED
2004-05-10
_CIPRODEX_ _®_ _ Product Monograph _ _Page 1 of 20_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr CIPRODEX ® Ciprofloxacin / Dexamethasone Otic Suspension 0.3% w/v (as ciprofloxacin hydrochloride) / 0.1% w/v Antibacterial - Corticosteroid (Otic) Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec H9S 1A9 Date of Revision: www.novartis.ca September 27, 2017 Submission Control No.: 206140 CIPRODEX ® is a registered trademark of Bayer, used with permission. _CIPRODEX_ _®_ _ Product Monograph _ _Page 2 of 20_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................6 DRUG INTERACTIONS ....................................................................................................8 DOSAGE AND ADMINISTRATION ................................................................................8 OVERDOSAGE ..................................................................................................................8 ACTION AND CLINICAL PHARMACOLOGY ..............................................................9 STORAGE AND STABILITY ............................................................................................9 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................10 PART II: SCIENTIFIC INFORMATION ................................................................................11 PHARMACEUTICAL INFORMATION ....................... Belgenin tamamını okuyun